Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Breast Cancer
DRUG: Pyrotinib Plus Trastuzumab|DRUG: Pertuzumab Plus Trastuzumab
PFS, Progression free survival, 6 weeks
Adverse Events, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 weeks
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.